Dose discontinuation
Fewer patients receiving BRAFTOVI + cetuximab discontinued therapy due to adverse events compared to control arm*
Rate of discontinuation primarily due to AEs (any grade) per updated post-hoc analysis 13
![Rate of discontinuation primarily](/sites/braftovi/files/2021-09/Rate-of-discontinuation-primarily.png)
- In patients treated with BRAFTOVI + cetuximab, the rate of all study drug discontinuation due to any adverse reaction was 1.9%1